Monatomics Technology

📍 Aix-en-Provence, France🗓 Founded 2015👥 1 employees💰 Last funded Dec 2015
Biotechnology Research🌐 monatomics-tech.com
Website LinkedIn
Monatomics Technology is a development stage company pioneering a novel inhalable gas mixture, consisting of xenon, helium, oxygen, and administered by a respiratory system that reduces neurotoxicity and thereby the risk of disability in acute ischemic stroke (AIS) patients. While today's Gold Standard therapies in AIS focus on the primary injury via thrombolysis and thrombectomy (or reperfusion), Monatomics focuses on the secondary injury generated by cerebral hypoxia in the ischemic penumbra via neuroprotection. The xenon acts as a neuroprotective agent by inhibiting the NMDA glutamate receptors and blocking the cascade of excitotoxicity. Monatomics' unique proprietary respiratory system recycles the xenon gas (thus making the solution commercially viable) and is scalable as it can be operated by any medical professional at any care setting - a significant hurdle in today's stroke reperfusion therapies.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2015
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Monatomics Technology?
Monatomics Technology has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Monatomics Technology last raise funding?
The most recent investment in Monatomics Technology recorded on gritt.io was in December 2015.
When was Monatomics Technology founded?
Monatomics Technology was founded in 2015.
What industry is Monatomics Technology in?
Monatomics Technology operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Monatomics Technology based?
Monatomics Technology is headquartered in Aix-en-Provence, France.